1 Erratum to: Clin Pharmacokinet (2014) 53(9):773–785 DOI 10.1007/s40262-014-0157-y
Page 778, Table 3: The last three rows which previously read:
Alogliptin 25 mgb (n = 2,679) | Placebo (n = 2,701) | ||
|---|---|---|---|
ALT >3 × ULN | 46 (1.7) | 64 (2.4) | 0.10 |
AST >3 × ULN | 43 (1.6) | 48 (1.8) | 0.67 |
Should read
Alogliptin 25 mgb (n = 2,701) | Placebo (n = 2,679) | ||
|---|---|---|---|
ALT >3 × ULN | 64 (2.4) | 46 (1.7) | 0.10 |
AST >3 × ULN | 48 (1.8) | 43 (1.6) | 0.67 |
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40262-014-0157-y.
Rights and permissions
About this article
Cite this article
Scheen, A.J. Erratum to: Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus. Clin Pharmacokinet 53, 1061 (2014). https://doi.org/10.1007/s40262-014-0205-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40262-014-0205-7